Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Intangibles: 2021-2025

Historic Intangibles for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $2.9 million.

  • InMed Pharmaceuticals' Intangibles changed negligibly% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.9 million for FY2025, which is negligibly% changed negligibly from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Intangibles of $2.9 million as of Q3 2025, which was down 0.00% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Intangibles peaked at $2.9 million during Q2 2023, and registered a low of $1.7 million during Q3 2021.
  • Moreover, its 3-year median value for Intangibles was $2.9 million (2025), whereas its average is $2.8 million.
  • Its Intangibles has fluctuated over the past 5 years, first declined by 25.19% in 2023, then surged by 47.34% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Intangibles (Quarterly) stood at $2.7 million in 2021, then decreased by 23.68% to $2.0 million in 2022, then spiked by 44.43% to $2.9 million in 2023, then remained steady at $2.9 million in 2024, then remained steady at $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.9 million for Q2 2025, and $2.9 million during Q1 2025.